Niaid division of allergy, immunology & transplantation: immune mediated diseases clinical products center (CPC)

Ended Definitive Contract Awarded Last action

Contract number
75N93019C00003
Awardee
Awarding agency
Obligated
$19,798,741

Award facts

Opportunity
Contract value 100% obligated
$19,798,740.82 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Set-aside
No set-aside
Competition
Full and Open Competition · 2 offers Negotiated Proposal / Quote
Pricing
Cost Plus Fixed Fee
Place of performance
Frederick, MD 21703, USA
Legislative mandates

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Change Order P00027 $980,085
Exercise an Option P00026 $384,150
Exercise an Option P00025 $1,699,689
Funding Only Action P00024 $226,289
Funding Only Action P00023 $308,000
Exercise an Option P00022 $1,110,193
Exercise an Option P00021 $1,654,048
Funding Only Action P00020 $645,000
Funding Only Action P00019 $222,000
Funding Only Action P00018 $1,200,000
Funding Only Action P00017 $54,336
Exercise an Option P00016 $1,973,686
Funding Only Action P00015 $400,000
Funding Only Action P00014 $451,630
Exercise an Option P00013 $900,000
Other Administrative Action P00012 $0
Exercise an Option P00011 $1,384,663
Funding Only Action P00010 $738,702
Funding Only Action P00009 $408,983
Exercise an Option P00008 $344,435
Exercise an Option P00007 $91,235
Exercise an Option P00006 $179,595
Exercise an Option P00005 $1,348,069
Supplemental Agreement for work within scope P00004 $175,874
Exercise an Option P00003 $169,228
Funding Only Action P00001 $156,672
Exercise an Option P00002 $1,312,948
Original award $1,279,231
Show all 28

About this award

Written by GovTribe AI ·

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a definitive cost-plus-fixed-fee contract to Eminent Services Corp on April 1, 2019, with a ceiling value of $19.8 million and completion targeted for March 31, 2026. The contract supports NIAID's Division of Allergy, Immunology & Transplantation and specifically focuses on the Immune Mediated Diseases Clinical Products Center (CPC), which conducts critical research on immune-related conditions. The work is performed in Frederick, Maryland, and no set-aside designation was applied to this competitive award. Eminent Services Corp, a minority-owned business enterprise headquartered in Frederick, brings specialized expertise in pharmaceutical logistics, biological services, and information technology support to federal agencies and the biotechnology sector.

This contract award reflects NIAID's reliance on Eminent Services Corp's demonstrated capabilities in cold chain logistics and temperature-sensitive pharmaceutical product management—core competencies essential for clinical research operations. The company's track record includes prior engagements with other National Institutes of Health components and sustained sub-grant work supporting diabetes research data coordination, positioning it as an established partner for NIH's specialized operational and administrative support needs. The extended performance period through 2026 indicates a substantial, ongoing commitment to supporting NIAID's immune-mediated disease research initiatives.

Quick answers

Who was awarded contract 75N93019C00003?

75N93019C00003 was awarded to Eminent Services Corp by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on April 1, 2019.

How much is contract 75N93019C00003 worth?

The government has obligated $19,798,741 on 75N93019C00003.

Was contract 75N93019C00003 competed?

The extent of competition for 75N93019C00003 was full and open competition. The government received 2 offers.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login